Month: May 2024

Verkkokauppa.com Oyj: Jesper Blomster appointed as new CFO and member of the management team in Verkkokauppa.com Oyj

Written by Customer Service on May 6, 2024. Posted in Public Companies.

Verkkokauppa.com Oyj STOCK EXCHANGE RELEASE 6 May 2024 at 2.00 p.m. EEST Jesper Blomster appointed as new CFO and member of the management team in Verkkokauppa.com Oyj MSc. (econ) Jesper Blomster (37) has been appointed as Chief Financial Officer (CFO) and a member of the management team in Verkkokauppa.com Oyj as of May 7, 2024. Blomster joins Verkkokauppa.com from Fiskars, where he has worked as SVP Finance and in other finance positions. Before Fiskars, he held various key finance positions, e.g. in Peak Performance, Kemira and Amer Sports. Current CFO Mikko Forsell will not continue working for Verkkokauppa.com. “I am very happy about the opportunity to start at Verkkokauppa.com. The company has progressed to an interesting stage on its journey, and I look forward to bringing my own know-how and experience to use for developing...

Boussard & Gavaudan Investment Management LLP: Form 8.3 –

Written by Customer Service on May 6, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Boussard & Gavaudan Investment Management LLP Boussard & Gavaudan Gestion SAS acting on behalf of various funds(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Network International Holdings PLC(d) If an exempt fund manager connected...

BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

Written by Customer Service on May 6, 2024. Posted in Earnings Releases And Operating Results.

Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low chemotherapy-naïve metastatic breast cancer patients, and a second Phase 3 trial with BNT323/DB-1303 in recurrent endometrial cancer planned to start soon Presented clinical data at the American Association for Cancer Research (“AACR”) Annual Meeting for individualized and off-the-shelf mRNA-based cancer vaccine candidates based on iNeST and FixVac platforms, including three-year follow-up data of an investigator-initiated trial in patients with resected pancreatic ductal adenocarcinoma (“PDAC”) Planning to share additional clinical data from multiple clinical programs at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, including bispecific...

USI Insurance Services Acquires Hignojos Insurance Agency

Written by Customer Service on May 6, 2024. Posted in Mergers And Acquisitions.

New Partnership Expands USI’s Texas-Based Presence and Expertise VALHALLA, N.Y., May 06, 2024 (GLOBE NEWSWIRE) — USI Insurance Services (“USI”), a world leader in risk management, employee benefit and retirement plan consulting, today announced the acquisition of Odessa, Texas-based Hignojos Insurance Agency. Founded in 2009, Hignojos Insurance Agency is an independent brokerage firm specializing in commercial and personal risk insurance programs. Terms of the transaction were not disclosed. “We are thrilled to be joining forces with USI, an established industry leader in the insurance brokerage and consulting market,” stated Hignojos Insurance Agency Principal, Louis Hignojos Sr. “Our valued clients throughout western Texas and beyond will continue to benefit from the local, personalized services they have come to expect from...

Integra LifeSciences Reports First Quarter 2024 Financial Results

Written by Customer Service on May 6, 2024. Posted in Earnings Releases And Operating Results.

PRINCETON, N.J., May 06, 2024 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2024. First Quarter 2024 HighlightsFirst quarter revenues of $368.9 million declined 3.1% on a reported basis and declined 2.5% on an organic basis compared to the prior year. Revenue increased 1.6% on an organic basis excluding BostonFirst quarter GAAP earnings per diluted share of $(0.04), compared to $0.29 in the prior year; adjusted earnings per diluted share of $0.55, compared to $0.74 in the prior yearCompleted the acquisition of the Acclarent, Inc. on April 1Updating full-year 2024 revenue guidance to a range of $1.672 billion to $1.687 billion from a range of $1.603 billion to $1.618 billion...

Oculis to Present at Bank of America Global Healthcare Conference

Written by Customer Service on May 6, 2024. Posted in Public Companies.

ZUG, Switzerland, and BOSTON, USA, May 06, 2024 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the Bank of America Healthcare Conference taking place on May 14-16, 2024 in Las Vegas, NV. Riad Sherif, M.D., Chief Executive Officer of Oculis, will deliver a company presentation on Wednesday, May 15th at 11:20am PT at the Encore Hotel. A live webcast of the presentation will be available here. The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their Bank of America representative to request meetings. A link to access company presentation, when available, will be...

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Written by Customer Service on May 6, 2024. Posted in Earnings Releases And Operating Results.

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%)1 compared to 1Q 2023 Successfully completed LOTIS-7 dose escalation and initiated expansion in 2L+ DLBCL Initial MZL IIT Phase 2 data from 15 patients showed 13 patients with CR and 1 patient with PR; encouraging data compared to current treatments in area with high unmet medical need Research event featured next-generation ADC platform and the Company’s most advanced ADC targets including promising preclinical data in NaPi2b, Claudin-6, PSMA and ASCT2 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the first quarter ended March 31,...

AI and Big Data Take the Centre Stage in Central Asia at Beetech 2024 Hosted by Beeline Kazakhstan and QazCode

Written by Customer Service on May 6, 2024. Posted in Public Companies.

More than 1000 participants discussed the future of AI and big data at the Beetech 2024.More than 1000 participants discussed the future of AI and big data at the Beetech 2024 organised by Beeline Kazakhstan and Qazcode in Astana on 27 April 2024 1000 Kazakh and international delegates participate in the annual conference, discussing artificial intelligence, big data analytics and app development in the region Amsterdam and Astana, 6 May 2024: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces that its digital operator Beeline Kazakhstan together with IT subsidiary QazCode, one of the country’s largest software firms, have hosted the 2024 Beetech Conference in Astana to discuss the future of AI, big data and application development. ...

Pulsar Helium Announces Spring Road Restrictions End at Topaz Project

Written by Customer Service on May 6, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) — Pulsar Helium Inc. (TSXV:PLSR & OTCQB:PSRHF) (“Pulsar” or the “Company”) is pleased to announce that the Minnesota Department of Transport has announced that Spring road restrictions in the north frost zone have ended (12:01 AM Monday, May 6). The Company will immediately recommence field operations at the Jetstream #1 appraisal well* at its flagship Topaz helium project. Activities will initially consist of road improvements and civil works, followed by down-hole logging, well completion, and flow testing with a pressure build up program. All necessary contracts are in place, with vendors and equipment secured to complete the upcoming works. Thomas Abraham-James, President and CEO said: “My colleagues and I are excited to obtain the outstanding data from Jetstream...

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Written by Customer Service on May 6, 2024. Posted in Public Companies.

Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA® All patients achieving responses maintained them at the time of data cutoff ZYNLONTA was generally well-tolerated and safety was consistent with known profile Data were presented at Lymphoma Research Foundation’s 2024 Marginal Zone Lymphoma Scientific Workshop LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL). The 50-patient single-arm, open-label Phase 2 multicenter...

Month: May 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals